Sale!

Opana

$125.00$215.00

Oxymorphone, sold under the brand names Numorphan and Opana among others, is an opioid pain medication. Opana ER (oxymorphone hydrochloride extended-release tablets) was first approved in 2006 for the management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

Clear

Description

Buy  Opana-Oxymorphone tablets Online

Oxymorphone (14-hyroxydihydromorphinone) is a potent schedule II opioid analgesic drug with an abuse liability similar to morphine and other schedule II opioids. Recently, there has been an increase in the abuse of  Oxymorphone. It was first marketed in the United States for medical use in 1959 as injectable and rectal suppository forms. In June 2006, Food and Drug Administration (FDA) approved immediate-release (IR) and extended-release (ER) oxymorphone oral tablets under brand names Opana® and Opana ER®

Licit Uses of oxymorphone (OPANA)

Oxymorphone is indicated for the relief of moderate to severe pain. It is currently marketed both as immediate release tablets containing 5 mg or 10 mg and as extended release tablets containing 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, or 40 mg oxymorphone hydrochloride. It is also available as 1mg/mL injectable formulation.

Chemistry/Pharmacology

Chemically, oxymorphone is 4,5α-epoxy-3,14-dihydroxy17-methylmorphinan-6-one, commonly used as its
hydrochloride salt – a white or slightly off-white, odorless powder, which is sparingly soluble in alcohol and ether, but freely soluble in water. Pharmacological and toxic effects, abuse, and dependence liabilities of oxymorphone are essentially similar to other schedule II opioid analgesics, such as morphine and oxycodone.

Oxymorphone is a pure opioid agonist relatively selective for the mu opioid receptors. However, at higher doses, it can interact with other opioid receptors. The precise mechanism of analgesic action of oxymorphone is unknown. Similar to pure opioid agonist analgesics, with increasing doses of oxymorphone there is increasing analgesia. There is no defined maximum dose; the ceiling to analgesic effectiveness is imposed only by serious side effects.

Effects and side effects of oxymorphone

Oxymorphone is a pure opioid agonist relatively selective for the mu opioid receptors. However, at higher doses, it can interact with other opioid receptors. The precise mechanism of analgesic action of oxymorphone is unknown. Similar to pure opioid agonist analgesics, with increasing doses of oxymorphone there is increasing analgesia. There is no defined maximum dose; the ceiling to analgesic effectiveness is imposed only by serious side effects.
In addition to analgesia, other pharmacological effects of opioid agonists include anxiolysis, euphoria, feelings of
relaxation, respiratory depression, constipation, miosis (contraction of pupils), and cough suppression.

Risk, dependence and overdose

Use of oxymorphone, similar to other schedule II opioid analgesics, carries the risk of addiction, physical dependence and/or tolerance. Abrupt discontinuation after prolonged use can cause signs and symptoms of opioid withdrawal.
Acute overdose of oxymorphone, similar to other pure opioid agonists, can produce severe respiratory depression,
somnolence (drowsiness) progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted
pupils, and reduction in blood pressure and heart rate. In some cases acute overdose may result in apnea, circulatory collapse, cardiac arrest, and death. Opioid receptor antagonist such as naloxone is a specific antidote against respiratory depression resulting from overdose or unusual sensitivity to oxymorphone.
Oxymorphone related deaths have been reported in various states.

Control Status

Oxymorphone is controlled in schedule II of the Controlled Substances Act.

 

Additional information

Quantity

30 tablets, 60 tablets, 90 tablets, 120 tablets

Reviews

There are no reviews yet.

Be the first to review “Opana”

Your email address will not be published. Required fields are marked *